Current Hypertension Reports最新文献_第4页

Longitudinal Insights Into Pediatric Hypertension, Cardiac Consequences, and Physical Activity. 儿童高血压、心脏后果和身体活动的纵向研究。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-03-03 DOI: 10.1007/s11906-026-01370-x

Douglas R Corsi, Andrew O Agbaje

{"title":"Longitudinal Insights Into Pediatric Hypertension, Cardiac Consequences, and Physical Activity.","authors":"Douglas R Corsi, Andrew O Agbaje","doi":"10.1007/s11906-026-01370-x","DOIUrl":"10.1007/s11906-026-01370-x","url":null,"abstract":"PURPOSE OF REVIEW: To summarize important novel but controversial discoveries in pediatric hypertension and prevention. This review also aims to provide some answers to previously unexpected findings in randomized clinical trials that failed to lower blood pressure in youth. RECENT FINDINGS: Emerging longitudinal investigations have elucidated the temporal progression of cardiac structural changes, revealing that arterial stiffness precedes the development of hypertension and cardiac remodeling. These temporal insights have important implications for physical activity interventions, as traditional recommendations emphasizing moderate-to-vigorous physical activity to lower blood pressure have demonstrated limited efficacy in randomized controlled trials. Recent evidence suggests that light physical activity provides superior blood pressure-lowering capacity compared to moderate-to-vigorous physical activity due to the confounding effect of muscle mass. Moreover, sedentary behavior may be a causal risk factor for progressive cardiovascular deterioration. Elevated blood pressure and hypertension during childhood and adolescence represent a critical risk factor for premature cardiovascular morbidity and mortality in adulthood. While the association between pediatric hypertension and adverse cardiovascular events is well-established, the temporal sequencing of pathophysiological mechanisms leading from blood pressure elevation to end-organ damage remains unclear. This comprehensive review synthesizes emerging evidence regarding the temporal relationships between pediatric hypertension and cardiac consequences, highlighting temporal trends that could inform evidence-based physical activity interventions for optimizing cardiovascular health trajectories from childhood through young adulthood. ","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12953251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypertension in Women Across the Life Cycle: Unique Aspects and Challenges. 高血压妇女在整个生命周期：独特的方面和挑战。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-02-20 DOI: 10.1007/s11906-026-01362-x

Rachel M Bond, Vikramjit Purewal, Natalie Cameron, Kardie Tobb, Demilade Adedinsewo, Ijeoma Isiadinso, Kameelah Phillips

{"title":"Hypertension in Women Across the Life Cycle: Unique Aspects and Challenges.","authors":"Rachel M Bond, Vikramjit Purewal, Natalie Cameron, Kardie Tobb, Demilade Adedinsewo, Ijeoma Isiadinso, Kameelah Phillips","doi":"10.1007/s11906-026-01362-x","DOIUrl":"10.1007/s11906-026-01362-x","url":null,"abstract":"Background: Hypertension is a major driver of cardiovascular morbidity and mortality in women, with risk trajectories that evolve across the female life course. From reproductive years through menopause, sex-specific biological, hormonal, and social factors contribute to unique patterns of blood pressure risk and cardiovascular vulnerability.Objective: To provide a life-course review of hypertension in adult women and highlight stage-specific risk factors, clinical considerations, and opportunities for prevention and management.Content: Women experience distinct exposures that influence hypertension risk, including hypertensive disorders of pregnancy, adverse pregnancy outcomes, psychosocial stressors, cardiometabolic changes, and the transition through menopause. This review integrates key recommendations from the 2025 American College of Cardiology/American Heart Association High Blood Pressure Guideline and emphasizes practical, stage-specific approaches to screening, risk stratification, and treatment tailored to women.Conclusions: A life-stage-specific, sex-informed approach to hypertension is essential to improve early identification, optimize treatment, and reduce long-term cardiovascular risk in women. Addressing persistent evidence gaps and prioritizing implementation of sex-specific care strategies will be critical to advancing equitable cardiovascular outcomes.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12923406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bridging the Gap in Racial/Ethnic Disparities: Perspectives from the 2025 American Heart Association/American College of Cardiology High Blood Pressure Guideline. 弥合种族/民族差异的差距：2025年美国心脏协会/美国心脏病学会高血压指南的观点

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-02-20 DOI: 10.1007/s11906-026-01367-6

Tina K Reddy, Bhavya Ancha, Jelani K Grant, Keith C Ferdinand

{"title":"Bridging the Gap in Racial/Ethnic Disparities: Perspectives from the 2025 American Heart Association/American College of Cardiology High Blood Pressure Guideline.","authors":"Tina K Reddy, Bhavya Ancha, Jelani K Grant, Keith C Ferdinand","doi":"10.1007/s11906-026-01367-6","DOIUrl":"10.1007/s11906-026-01367-6","url":null,"abstract":"Purpose of review: High blood pressure is a leading cause of cardiovascular disease (CVD) morbidity and mortality worldwide, disproportionately affecting racial/ethnic populations in the United States (US). This review summarizes racial/ethnic inequities in CVD risk, hypertension (HTN), and the social determinants or drivers of health (SDOH), highlighting the 2025 American Heart Association/American College of Cardiology (AHA/ACC) High Blood Pressure Guideline.Recent findings: Certain US racial/ethnic populations experience disproportionate HTN burden, with Black adults demonstrating higher rates of resistant, nocturnal and masked HTN, hypertensive disorders of pregnancy, and dementia and cognitive decline. The 2025 AHA/ACC High Blood Pressure Guideline emphasizes the use of a novel race-neutral CVD risk calculator to guide initiation of pharmacotherapy, utilizing patient counseling and shared decision-making, alongside team-based, community-engaged HTN management strategies. The 2025 AHA/ACC High Blood Pressure Guideline advances health equity, integrating the SDOH into improved CVD risk assessment and management recommendations. Effective mitigation of disparities to improve blood pressure and CVD outcomes demands optimizing healthcare access, addressing systemic discrimination, incorporating social context into shared clinical-decision making, and deploying culturally-tailored, community-based interventions.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":"13"},"PeriodicalIF":6.3,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146225853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insomnia and Hypertension: Importance of Objective Phenotyping and Comorbidity with Sleep Apnea. 失眠和高血压：客观表型和睡眠呼吸暂停合并症的重要性。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-02-09 DOI: 10.1007/s11906-026-01365-8

Nikolaos Athanasiou, Alexandros N Vgontzas, Julio Fernandez-Mendoza

{"title":"Insomnia and Hypertension: Importance of Objective Phenotyping and Comorbidity with Sleep Apnea.","authors":"Nikolaos Athanasiou, Alexandros N Vgontzas, Julio Fernandez-Mendoza","doi":"10.1007/s11906-026-01365-8","DOIUrl":"10.1007/s11906-026-01365-8","url":null,"abstract":"Purpose of review: Provide a synthesis of research from the past five years examining the relationship between insomnia, its phenotypes, and comorbidity with sleep apnea (COMISA), with hypertension. Offer a critical evaluation of current evidence and outline future research directions.Recent findings: Meta-analytic evidence indicates that the risk of hypertension is higher in patients with insomnia disorder compared to those with insomnia symptoms, with the highest risk observed in the insomnia with objective short sleep duration phenotype. COMISA appears to further amplify this risk, although the evidence is limited to individual studies with no meta-analyses available. There is a clear need for clinical trials to confirm these associations and guide the development of more effective therapeutic strategies. Insomnia should be part of the diagnostic assessment of patients with hypertension. Objective sleep duration can serve as a biomarker, alongside respiratory indices, to guide therapeutic decision-making and optimize patient management.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":"12"},"PeriodicalIF":6.3,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12886293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric Ambulatory Blood Pressure Patterns and Cardiovascular Risk. 儿科动态血压模式和心血管风险。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-01-30 DOI: 10.1007/s11906-026-01361-y

Jordan Sill, Elaine Urbina

{"title":"Pediatric Ambulatory Blood Pressure Patterns and Cardiovascular Risk.","authors":"Jordan Sill, Elaine Urbina","doi":"10.1007/s11906-026-01361-y","DOIUrl":"10.1007/s11906-026-01361-y","url":null,"abstract":"PURPOSE OF REVIEW: Pediatric hypertension is associated with antecedent cardiovascular (CV) risk factors and the subsequent development of early subclinical CV disease. Current guidelines recommend the use of ambulatory blood pressure monitoring (ABPM) to diagnose and classify pediatric hypertension into distinct patterns. In recent years, emerging literature has explored the risk factors linked to these ABPM patterns and the associations of these patterns with target organ damage. This review summarizes studies published in the past five years that examine pediatric ABPM patterns and their relationship to cardiovascular risk. RECENT FINDINGS: ABPM can be used to diagnose hypertension patterns, such as masked hypertension and non-dipping, that can not be identified through office-based measurements alone. This review of recent studies highlights multisystem risk factors that are associated with abnormal ABPM patterns in youth. It also presents growing evidence linking these patterns to target organ damage across pediatric populations with varying cardiovascular risk profiles. Ambulatory blood pressure patterns in pediatric patients can be used to stratify cardiovascular risk in youth, before the onset of cardiovascular events. ","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":"11"},"PeriodicalIF":6.3,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12858476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing Hypertension Treatment Disparities Via Renal Denervation. 通过肾去神经处理高血压治疗差异。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-01-21 DOI: 10.1007/s11906-025-01359-y

Bernardo F Spiazzi, Carolina P Zingano, Luke J Laffin

引用次数: 0

Patient Selection and Renal Denervation. 患者选择和肾去神经。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-01-21 DOI: 10.1007/s11906-025-01360-5

Ankita Ashoka, Raven Voora

{"title":"Patient Selection and Renal Denervation.","authors":"Ankita Ashoka, Raven Voora","doi":"10.1007/s11906-025-01360-5","DOIUrl":"10.1007/s11906-025-01360-5","url":null,"abstract":"PURPOSE OF REVIEW: To review the current data informing patient selection and provide guidance on when to refer potential patients for consideration of renal denervation. RECENT FINDINGS: Multiple sham-controlled randomized trials have demonstrated favorable safety and efficacy outcomes for renal denervation (RDN) in the management of uncontrolled hypertension in patients across the hypertension (HTN) spectrum including patients with true resistant hypertension (TRH) and in patients both on and off antihypertensive therapy. In addition, sustained reductions in BP up to 3 years have been observed. Based on these favorable findings, guidelines and position papers recommend RDN as an adjunct to antihypertensive medications and lifestyle modifications in patients with uncontrolled hypertension and increased risk of cardiovascular (CV) complications like TRH patients and in patients who are unable or unwilling to optimize medical therapy for uncontrolled hypertension. However, data on RDN safety and efficacy remain limited in chronic kidney disease (CKD) and isolated systolic hypertension (ISH). Another area of active investigation is the identification of predictors of response to RDN which could help refine criteria for patient selection. Selection of patients for RDN requires an evaluation of the hypertension prior to referral in addition to engaging patients in shared decision-making (SDM). It is also recommended that patients being considered for RDN be evaluated by a multidisciplinary team who is knowledgeable about hypertension and RDN. RDN is an adjunct to lifestyle modification and medications for the treatment of hypertension. Appropriate patient selection for RDN is based on populations studied in clinical trials and should include a comprehensive evaluation of the uncontrolled hypertension prior to referral. ","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":"10"},"PeriodicalIF":6.3,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiometabolic Surgery for Treatment of Hypertension. 心脏代谢手术治疗高血压。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-01-08 DOI: 10.1007/s11906-025-01355-2

Carlos Aurelio Schiavon, Luciano Ferreira Drager

引用次数: 0

The Role of Mineralocorticoid Receptors in the Treatment of Primary Hypertension. 矿化皮质激素受体在原发性高血压治疗中的作用。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-01-05 DOI: 10.1007/s11906-025-01358-z

Jehan Zahid Bahrainwala, Vivek Bhalla

{"title":"The Role of Mineralocorticoid Receptors in the Treatment of Primary Hypertension.","authors":"Jehan Zahid Bahrainwala, Vivek Bhalla","doi":"10.1007/s11906-025-01358-z","DOIUrl":"10.1007/s11906-025-01358-z","url":null,"abstract":"Hypertension affects over one billion individuals worldwide and remains the leading modifiable risk factor for cardiovascular disease. While first-line therapies including thiazide-type diuretics, angiotensin converting enzyme inhibitors / angiotensin receptor blockers, and calcium channel blockers can effectively control blood pressure in many patients, 10-20% develop resistant hypertension requiring additional therapeutic approaches. Steroidal mineralocorticoid receptor antagonists (MRAs) have emerged as essential fourth-line agents for resistant hypertension, with spironolactone demonstrating superior efficacy compared to other add-on therapies in the landmark PATHWAY-2 trial. The pathophysiological rationale for MRAs includes natriuretic effects, vasodilatory properties and target organ protection through anti-fibrotic mechanisms. Novel non-steroidal MRAs offer improved selectivity and reduced endocrine side effects compared to traditional agents, potentially expanding the therapeutic window for mineralocorticoid receptor blockade. In this review, we discuss the established role of MRAs in primary and resistant hypertension management and discuss consideration of MRAs in certain hypertension patient populations. We also briefly review patient selection strategies and future directions for this important therapeutic class.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":"7"},"PeriodicalIF":6.3,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145898979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obstructive Sleep Apnea and Hypertension: Is Aldosterone Blockade the Optimal Approach to Control Blood Pressure and Improve Oxygenation? 阻塞性睡眠呼吸暂停和高血压：醛固酮阻断是控制血压和改善氧合的最佳途径吗？

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-01-03 DOI: 10.1007/s11906-025-01356-1

Allison K Ikeda, Reena Mehra

{"title":"Obstructive Sleep Apnea and Hypertension: Is Aldosterone Blockade the Optimal Approach to Control Blood Pressure and Improve Oxygenation?","authors":"Allison K Ikeda, Reena Mehra","doi":"10.1007/s11906-025-01356-1","DOIUrl":"10.1007/s11906-025-01356-1","url":null,"abstract":"Purpose of review: Obstructive sleep apnea (OSA) is common and strongly linked with systemic hypertension, including resistant and nocturnal forms. Traditional OSA therapies lead to modest blood pressure (BP) reductions, but optimal antihypertensive strategies in this population remain unclear. This review examines OSA driven hypertension mechanisms, differential responses to standard OSA therapies, and evaluates evidence for mineralocorticoid-targeted treatment - including blockade of aldosterone - as a tailored BP lowering and airway improving strategy.Recent findings: OSA promotes hypertension via intermittent hypoxia, sympathetic overactivity, sleep fragmentation, renin-angiotensin-aldosterone system (RAAS)-mediated fluid retention, and nocturnal fluid shifts that increase airway collapsibility. While continuous positive airway pressure (CPAP), oral appliances, weight loss, and other standard OSA therapies consistently yield modest BP reductions (typically 2-5 mmHg), patients with resistant hypertension, obesity, or high CPAP adherence derive greater benefit. Recent clinical studies demonstrate that mineralocorticoid receptor antagonists (MRAs) such as spironolactone or eplerenone reduce both apnea-hypopnea index (AHI) and BP in OSA patients with resistant hypertension. Emerging data from trials of selective aldosterone synthase inhibitors (ASIs) support meaningful BP reduction in obese hypertensive individuals with data on OSA specific outcomes remain forthcoming.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":"6"},"PeriodicalIF":6.3,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145891952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0